Rafferty Asset Management, LLC Krystal Biotech, Inc. Transaction History

Rafferty Asset Management, LLC

$28.9 Billion
Q3 2024

A detailed history of Rafferty Asset Management, LLC transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Rafferty Asset Management, LLC holds 45,840 shares of KRYS stock, worth $8.16 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares

45,840

Previous 41,800 9.67%

Holding current value

$8.16 Million

Previous $7.68 Million 8.6%

% of portfolio

0.03%

Previous 0.03%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$174.7 - $213.66 $705,788 - $863,186	4,040 Added 9.67%	45,840 $8.34 Million
Q2 2024 Aug 13, 2024	SELL	$153.12 - $183.64 $1.77 Million - $2.12 Million	-11,567 Reduced 21.67%	41,800 $7.68 Million
Q1 2024 May 13, 2024	SELL	$108.01 - $179.35 $3.31 Million - $5.5 Million	-30,654 Reduced 36.48%	53,367 $9.5 Million
Q4 2023 Feb 13, 2024	BUY	$96.0 - $128.29 $1.17 Million - $1.57 Million	12,215 Added 17.01%	84,021 $10.4 Million
Q3 2023 Nov 13, 2023	BUY	$108.51 - $130.22 $2.02 Million - $2.43 Million	18,623 Added 35.02%	71,806 $8.33 Million
Q2 2023 Aug 11, 2023	SELL	$78.48 - $130.32 $654,601 - $1.09 Million	-8,341 Reduced 13.56%	53,183 $6.24 Million
Q1 2023 May 11, 2023	SELL	$72.39 - $84.27 $7,311 - $8,511	-101 Reduced 0.16%	61,524 $4.93 Million
Q4 2022 Feb 13, 2023	BUY	$63.14 - $79.9 $591,558 - $748,583	9,369 Added 17.93%	61,625 $4.88 Million
Q3 2022 Nov 14, 2022	BUY	$64.85 - $82.4 $1.24 Million - $1.57 Million	19,064 Added 57.44%	52,256 $3.64 Million
Q2 2022 Aug 12, 2022	SELL	$48.93 - $73.47 $1.31 Million - $1.97 Million	-26,820 Reduced 44.69%	33,192 $2.18 Million
Q1 2022 May 13, 2022	BUY	$51.99 - $72.11 $1.43 Million - $1.98 Million	27,519 Added 84.69%	60,012 $3.99 Million
Q4 2021 Feb 10, 2022	BUY	$39.81 - $88.24 $367,804 - $815,249	9,239 Added 39.73%	32,493 $2.27 Million
Q3 2021 Nov 10, 2021	BUY	$52.01 - $71.77 $46,392 - $64,018	892 Added 3.99%	23,254 $1.21 Million
Q2 2021 Aug 10, 2021	SELL	$62.14 - $81.82 $223,455 - $294,224	-3,596 Reduced 13.85%	22,362 $1.52 Million
Q1 2021 May 10, 2021	BUY	$59.42 - $85.46 $1.29 Million - $1.85 Million	21,665 Added 504.66%	25,958 $2 Million
Q4 2020 Feb 10, 2021	SELL	$40.64 - $61.38 $354,868 - $535,970	-8,732 Reduced 67.04%	4,293 $258,000
Q3 2020 Nov 13, 2020	BUY	$37.76 - $48.49 $200,128 - $256,997	5,300 Added 68.61%	13,025 $561,000
Q2 2020 Aug 07, 2020	BUY	$37.03 - $60.0 $286,056 - $463,500	7,725 New	7,725 $320,000
Q1 2020 May 15, 2020	SELL	$35.02 - $65.64 $438,520 - $821,944	-12,522 Closed	0 $0
Q4 2019 Feb 10, 2020	SELL	$33.17 - $65.23 $468,028 - $920,395	-14,110 Reduced 52.98%	12,522 $693,000
Q3 2019 Nov 14, 2019	BUY	$34.72 - $51.3 $924,663 - $1.37 Million	26,632 New	26,632 $925,000

Others Institutions Holding KRYS

# of Institutions

310

Shares Held

24.4M

Call Options Held

483K

Put Options Held

364K

View Full List

About Krystal Biotech, Inc.

Ticker KRYS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,664,300
Market Cap $4.57B
Description
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...

More about KRYS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rafferty Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Rafferty Asset Management, LLC with notifications on news.

Account

Rafferty Asset Management, LLC Krystal Biotech, Inc. Transaction History